Earnings Call · Q2 FY2022·2022-08-06

Q2 22EPS -19.05%·Rev n/aQ1 22EPS -64.71%·Rev n/aQ4 21EPS +100.00%*·Rev n/aQ3 21EPS +8.22%·Rev n/a⚠ consensus missing

Voyager Therapeutics, Inc. VYGR

Julie Burek — Investor Relations

Dr. Al Sandrock — Chief Executive Officer

−7.2%1d on move date−7.1% vs SPY3d−18.2%5d−13.3%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more VYGR calls or request research access.

More VYGR calls Browse calls Request research access